rs2371365 — PCLO PCLO Presynaptic Scaffold

Piccolo: The Synapse's Master Organizer and Mood Risk

Every time a neuron signals its neighbor, a precisely choreographed event unfolds at the presynaptic terminal: calcium floods in, synaptic vesicles fuse with the membrane, and neurotransmitters flood the synapse. Orchestrating this entire process is a giant scaffolding protein called Piccolo¹¹ Piccolo
encoded by the PCLO gene, located at chromosome 7q11.23. Piccolo anchors calcium channels, tethers vesicles, and coordinates the actin cytoskeleton that drives vesicle recycling. Without it functioning optimally, the timing and magnitude of neurotransmitter release — including serotonin, dopamine, and norepinephrine — can go subtly awry.

rs2371365 is an intronic variant in PCLO that sits approximately 53 kb from rs2522833, the functional missense variant (Ser4814Ala) that was the top association signal in the first genome-wide study of major depressive disorder to implicate this gene. As an intronic SNP in moderate linkage disequilibrium with the coding variant region, rs2371365 is a proxy marker for the broader PCLO risk haplotype rather than a direct functional mutation itself.

The Mechanism

The PCLO Ser4814Ala substitution (rs2522833), with which rs2371365 is in partial LD²² partial LD
linkage disequilibrium; both variants tag the same 167 kb PCLO risk haplotype identified by Sullivan et al., resides near a C2 calcium-binding domain of the Piccolo protein. C2 domains are calcium sensors that trigger phospholipid binding and vesicle fusion events. Functional studies in cultured neurons carrying the Ser4814Ala substitution showed 30% increased excitatory synaptic transmission and elevated Piccolo protein levels at synapses³³ 30% increased excitatory synaptic transmission and elevated Piccolo protein levels at synapses
Giniatullina et al. 2015; these changes suggest compensatory upregulation in response to altered C2 calcium sensing.

At the cellular level, Piccolo also regulates presynaptic F-actin assembly by scaffolding actin regulatory proteins including Daam1. When Piccolo is disrupted, boutons show enhanced activity-dependent vesicle exocytosis and reduced F-actin polymerization⁴⁴ boutons show enhanced activity-dependent vesicle exocytosis and reduced F-actin polymerization
Waites et al. 2011, J Neurosci; loss of Piccolo function paradoxically increases short-term exocytosis while impairing sustainable vesicle recycling, which may dysregulate monoamine release dynamics across serotonergic, dopaminergic, and noradrenergic synapses in the brainstem and limbic system.

The Evidence

The initial genome-wide association study by Sullivan et al. 2009 in Molecular Psychiatry⁵⁵ Sullivan et al. 2009 in Molecular Psychiatry
1,738 MDD cases vs. 1,802 controls; identified 11 genome-wide signals in a 167 kb PCLO region; top hit rs2715148 p=7.7×10⁻⁷, rs2522833 p=1.2×10⁻⁶ was the first to implicate PCLO in major depressive disorder. A population-based replication by Hek et al. 2010⁶⁶ Hek et al. 2010
579 depression cases, 912 controls; confirmed rs2522833 association, p=0.0025; meta-analysis across three population-based studies reached p=1.93×10⁻⁹ brought the evidence to genome-wide significance.

The most striking findings concern the brain's emotional processing circuitry. An fMRI study by Woudstra et al. 2012⁷⁷ fMRI study by Woudstra et al. 2012
22 MDD patients and 29 healthy controls; PCLO risk allele carriers showed significantly increased left amygdala activity during angry and sad face processing; effects on fearful faces were specific to MDD demonstrated that PCLO risk allele carriers — regardless of depression status — show heightened amygdala reactivity. A follow-up study examining emotional memory⁸⁸ emotional memory
Woudstra et al. 2013, PLoS One; N=89 MDD and 29 controls; risk carriers showed reduced striatal encoding of negative words and blunted amygdalar response to novel positive stimuli found that risk carriers also show blunted reward signaling, consistent with the anhedonia that characterizes major depression.

Personality correlates were documented by Minelli et al. 2012⁹⁹ Minelli et al. 2012
522 MDD patients, 375 controls; CC homozygotes significantly overrepresented in depressed group, p<0.01; C-allele carriers in controls showed elevated Harm Avoidance and reduced Novelty Seeking on the Tridimensional Personality Questionnaire, suggesting the risk variant shapes temperamental traits that predispose toward depression before a clinical episode occurs.

At the neuroendocrine level, Schuhmacher et al. 2011¹⁰¹⁰ Schuhmacher et al. 2011
205 depressed inpatients followed through 4-week antidepressant treatment; C-allele carriers showed greater initial HPA axis reactivity and stronger hormonal responsiveness during treatment linked PCLO genotype to stress hormone regulation, a core feature of melancholic depression.

Practical Actions

Carriers of one or two C alleles at rs2371365 appear to have a subtly altered presynaptic environment, particularly in monoaminergic circuits governing emotional processing. This does not predict depression deterministically — the variant contributes a modest shift in baseline emotional reactivity and stress system tone. Practical steps focus on protecting monoamine system resilience, stabilizing presynaptic calcium signaling, and supporting HPA axis regulation.

The heightened amygdala reactivity documented in risk carriers makes cognitive-reappraisal and mindfulness-based interventions particularly relevant as they act specifically on amygdala-prefrontal circuitry. Monitoring via validated mood self-tracking (PHQ-9 or GAD-7) gives early warning before subclinical symptoms progress. If antidepressants are ever needed, the HPA axis modulation data suggest PCLO genotype may eventually inform treatment selection.

Interactions

The strongest documented interaction involves rs2522833 in PCLO itself: rs2371365 is a proxy marker for the same risk haplotype, so both variants in the same person are likely tagging the same underlying biological signal rather than independent effects. If rs2522833 data is available, that missense variant has more direct functional evidence.

PCLO risk has also been examined in the context of serotonin transporter (5-HTTLPR, rs25531) and BDNF Val66Met (rs6265) variation; epistatic analyses suggest additive or synergistic effects on limbic reactivity when multiple monoamine pathway variants co-occur, though published compound analyses remain limited.